MANDEEP BAJAJ to Disease Models, Animal
This is a "connection" page, showing publications MANDEEP BAJAJ has written about Disease Models, Animal.
Connection Strength
0.141
-
Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia. 2011 Dec; 54(12):3093-100.
Score: 0.046
-
Acupuncture Reduces Hypertrophy and Cardiac Fibrosis, and Improves Heart Function in Mice with Diabetic Cardiomyopathy. Cardiovasc Drugs Ther. 2020 12; 34(6):835-848.
Score: 0.021
-
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes. Cardiovasc Drugs Ther. 2018 04; 32(2):135-145.
Score: 0.018
-
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017 Apr; 31(2):119-132.
Score: 0.017
-
Ubc9 Impairs Activation of the Brown Fat Energy Metabolism Program in Human White Adipocytes. Mol Endocrinol. 2015 Sep; 29(9):1320-33.
Score: 0.015
-
Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovasc Drugs Ther. 2012 Dec; 26(6):445-56.
Score: 0.012
-
Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes. Am J Physiol Heart Circ Physiol. 2013 Jan 01; 304(1):H131-41.
Score: 0.012